Boston Scientific Faces Class Action Lawsuit Over Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy BSX?
Source: Globenewswire
Boston Scientific Corp's stock fell by 5.01% as it crossed below the 5-day SMA, reflecting investor concerns amid ongoing legal challenges.
The company is facing a class action lawsuit for alleged violations of federal securities laws, with plaintiffs claiming that Boston Scientific made materially false statements regarding the growth of its U.S. electrophysiology segment. This lawsuit has raised significant concerns among investors, particularly as the company previously issued optimistic growth forecasts despite known competitive pressures. The legal action is prompting investors to reconsider their positions, leading to a decline in stock price despite broader market gains.
This situation highlights the potential risks associated with the company's growth narrative and may lead to increased volatility in its stock as the legal proceedings unfold.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 65.690
Low
94.00
Averages
108.14
High
132.00
Current: 65.690
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BOSTON SCIENTIFIC CORP.: BARCLAYS LOWERS TARGET PRICE FROM $100 TO $96
Barclays Adjusts Target Price: Barclays has reduced its target price for a specific stock from $100 to $96.
Market Implications: This adjustment may reflect changing market conditions or company performance expectations.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, leading to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS in 2017, highlighting its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record to ensure effective representation in the class action, avoiding firms that merely act as intermediaries.
See More
Boston Scientific Shares Surge 8.99% After Q1 Earnings Beat
- Earnings Beat: Boston Scientific's Q1 sales and adjusted EPS rose by 9% and 6%, respectively, surpassing Wall Street estimates; despite lowering its full-year sales growth guidance from 10.5% to 7.25%, the stock surged 8.99%, indicating market confidence in its growth prospects.
- Surge in Trading Volume: Today's trading volume reached 40.4 million shares, approximately 138% above the three-month average of 17 million shares, reflecting strong investor interest and a positive shift in market sentiment following the earnings report.
- Price Volatility Context: Despite today's gains, Boston Scientific's stock has declined by 37% over the past six months, highlighting cautious market sentiment, particularly after disappointing clinical trial data on its heart implant device released three weeks ago.
- Investor Focus: Since its IPO in 1992, Boston Scientific has seen a 1,415% increase in stock price, and despite recent challenges, it remains an attractive option for medical device investors, especially given its current valuation at just 19 times forward earnings.
See More
U.S. Stocks Rise, Nasdaq Hits Record High
- Nasdaq Hits Record High: The Nasdaq 100 rose by 1.73%, reaching a new record high, reflecting strong investor confidence in tech stocks, particularly driven by robust corporate earnings, which may attract further investment in the tech sector.
- Earnings Beat Expectations: Companies like GE, Boeing, and Masco reported Q1 revenues of $9.34 billion, negative $1.45 billion, and $1.92 billion respectively, all exceeding market expectations, which boosted overall market sentiment and indicated signs of economic recovery.
- Oil Price Surge Affects Markets: WTI crude oil prices rose over 3% due to the blockade of the Strait of Hormuz, potentially exacerbating the global energy crisis and influencing market inflation expectations, thereby affecting investor risk appetite.
- Mortgage Applications Increase: U.S. MBA mortgage applications rose by 7.9% in the week ending April 17, with the purchase mortgage sub-index up 10.1%, indicating a rebound in housing demand that could positively impact the real estate market.
See More
Boston Scientific Receives Upgrade with Price Target of $95.97
- Rating Upgrade: Boston Scientific (BSX) has received a buy rating, indicating market confidence in its future performance, which is likely to attract more investor interest.
- Price Target Insight: The average price target set by analysts is $95.97, reflecting an optimistic outlook on the company's growth potential, which could drive the stock price higher.
- Market Reaction: This rating upgrade may stimulate short-term stock price volatility, attracting more trading activity and enhancing market liquidity.
- Investor Confidence: With the rating increase, investor confidence in Boston Scientific is expected to strengthen, potentially facilitating further advancements in the medical device sector.
See More
Analysis of Significant Stock Movements Among Companies
- Calix Stock Decline: Calix's shares fell 16% after the company warned of margin pressures for the year, overshadowing better-than-expected first-quarter results, indicating investor concerns about future profitability.
- TE Connectivity Guidance Miss: TE Connectivity's stock dropped 12% as the company's second-quarter guidance of $2.65 EPS and $4.7 billion revenue aligned with FactSet consensus but failed to inspire investor confidence, leading to downward pressure on the stock.
- Healthcare Services Group Strong Performance: Healthcare Services Group's shares surged 18% after reporting a first-quarter profit of $0.37 per share and revenue of $462.8 million, both exceeding analyst expectations, showcasing the company's competitive edge and growth potential in the market.
- United Airlines Guidance Cut: United Airlines shares fell 6% after the company provided disappointing guidance for the current quarter and full year, expecting adjusted earnings of $7 to $11 per share for 2026, down from prior estimates of $12 to $14, reflecting rising fuel price pressures.
See More
BOSTON SCIENTIFIC CORP.: BARCLAYS LOWERS TARGET PRICE FROM $100 TO $96
Barclays Adjusts Target Price: Barclays has reduced its target price for a specific stock from $100 to $96.
Market Implications: This adjustment may reflect changing market conditions or company performance expectations.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, leading to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS in 2017, highlighting its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record to ensure effective representation in the class action, avoiding firms that merely act as intermediaries.
See More
Boston Scientific Shares Surge 8.99% After Q1 Earnings Beat
- Earnings Beat: Boston Scientific's Q1 sales and adjusted EPS rose by 9% and 6%, respectively, surpassing Wall Street estimates; despite lowering its full-year sales growth guidance from 10.5% to 7.25%, the stock surged 8.99%, indicating market confidence in its growth prospects.
- Surge in Trading Volume: Today's trading volume reached 40.4 million shares, approximately 138% above the three-month average of 17 million shares, reflecting strong investor interest and a positive shift in market sentiment following the earnings report.
- Price Volatility Context: Despite today's gains, Boston Scientific's stock has declined by 37% over the past six months, highlighting cautious market sentiment, particularly after disappointing clinical trial data on its heart implant device released three weeks ago.
- Investor Focus: Since its IPO in 1992, Boston Scientific has seen a 1,415% increase in stock price, and despite recent challenges, it remains an attractive option for medical device investors, especially given its current valuation at just 19 times forward earnings.
See More
U.S. Stocks Rise, Nasdaq Hits Record High
- Nasdaq Hits Record High: The Nasdaq 100 rose by 1.73%, reaching a new record high, reflecting strong investor confidence in tech stocks, particularly driven by robust corporate earnings, which may attract further investment in the tech sector.
- Earnings Beat Expectations: Companies like GE, Boeing, and Masco reported Q1 revenues of $9.34 billion, negative $1.45 billion, and $1.92 billion respectively, all exceeding market expectations, which boosted overall market sentiment and indicated signs of economic recovery.
- Oil Price Surge Affects Markets: WTI crude oil prices rose over 3% due to the blockade of the Strait of Hormuz, potentially exacerbating the global energy crisis and influencing market inflation expectations, thereby affecting investor risk appetite.
- Mortgage Applications Increase: U.S. MBA mortgage applications rose by 7.9% in the week ending April 17, with the purchase mortgage sub-index up 10.1%, indicating a rebound in housing demand that could positively impact the real estate market.
See More
Boston Scientific Receives Upgrade with Price Target of $95.97
- Rating Upgrade: Boston Scientific (BSX) has received a buy rating, indicating market confidence in its future performance, which is likely to attract more investor interest.
- Price Target Insight: The average price target set by analysts is $95.97, reflecting an optimistic outlook on the company's growth potential, which could drive the stock price higher.
- Market Reaction: This rating upgrade may stimulate short-term stock price volatility, attracting more trading activity and enhancing market liquidity.
- Investor Confidence: With the rating increase, investor confidence in Boston Scientific is expected to strengthen, potentially facilitating further advancements in the medical device sector.
See More
Analysis of Significant Stock Movements Among Companies
- Calix Stock Decline: Calix's shares fell 16% after the company warned of margin pressures for the year, overshadowing better-than-expected first-quarter results, indicating investor concerns about future profitability.
- TE Connectivity Guidance Miss: TE Connectivity's stock dropped 12% as the company's second-quarter guidance of $2.65 EPS and $4.7 billion revenue aligned with FactSet consensus but failed to inspire investor confidence, leading to downward pressure on the stock.
- Healthcare Services Group Strong Performance: Healthcare Services Group's shares surged 18% after reporting a first-quarter profit of $0.37 per share and revenue of $462.8 million, both exceeding analyst expectations, showcasing the company's competitive edge and growth potential in the market.
- United Airlines Guidance Cut: United Airlines shares fell 6% after the company provided disappointing guidance for the current quarter and full year, expecting adjusted earnings of $7 to $11 per share for 2026, down from prior estimates of $12 to $14, reflecting rising fuel price pressures.
See More
